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Smmuary Alkelic loss is a common mechanism of inactivation of tumour-suppressor genes in colorectal
carcinomas. A number of known or putative tumour-suppressor genes including NFl, BRCA1, NMEI, NME2
and prohibitin are present on the long arm of chromosome 17, and this region has not been extensively
analysed in colorectal tumours. In this study 72 colorectal carcinomas were examined for allelic loss at eight
loci on chromosome 17. Allelic loss was frequent both at the p53 locus, which is known to be important in
colorectal carcinoma, and also telomeric to p53 on 17p. Alkelic loss continued to be present in more than 50%
of cases in the pericentromeric region and on proximal 17q to the markler LEWIOI (D17S40) at 17q22-23.
The most telomeric markers on 17q showed lower rates of allelic loss. Analysis of cases with partial deletions
which did not include the p53 locus showed a common region of overlap of the deletions centred on D17S40.
This suggests the target of allelic loss on 17q is a tumour-suppressor gene in this region.
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Inactivation of tumour-suppressor genes is an important
mechanism underlying the initiation and progression of colo-
rectal tumours. A common method of inactivation is loss of
one allele, often with a mutation in the remaining allele
(Weinberg, 1991). This can be observed as loss of heterozy-
gosity (LOH). It is proposed that colorectal tumorigenesis is
a multistep process driven by progressive inactivation of
multiple tumour-suppressor genes and activation of at least
one oncogene, K-ras (Fearon and Vogelstein, 1990). Allelic
loss and mutation of the APC and MCC genes on chromo-
some 5q occurs early in tumorigenesis. In carcinomas, LOH
is most frequent on chromosomes 17p (75%) and 18q (73%)
(Vogelstein et al., 1989).
Chromosome 17p harbours the known tumour-suppressor
gene p53. The identification of inactivating mutations in the
majority of the remaining p53 alleles adds further evidence
that p53 is important in colorectal tumorigenesis (Baker et
al., 1990). However, little analysis has been done of 17q, on
which many candidate tumour-suppressor genes reside. One
report showed that most carcinomas with loss on 17p retain-
ed both alleles on distal 17q when tested with the probe
THH 59 mapping to bands 17q22 to 17q25.2 (Vogelstein et
al., 1988).
The putative metastasis-suppressor gene NME1 (also refer-
red to as nm23-Hl) has been mapped to 17q22 (Varesco et
al., 1992). Initially allelic loss of NME1 was found in 22% of
colorectal tumours (Leone et al., 1991). A later study sug-
gested that NME1 allelic deletions, occurring in 52% of
tumours, are an important prognostic marker in colorectal
carcinoma (Cohn et al., 1991). A further report also sug-
gested an association with metastasis but only found dele-
tions in 4 of 20 tumours (Wang et al., 1993). A second
closely related gene, NME2, is located very close to NME1
(Backer et al., 1993: Chandrasekharappa et al., 1993).
Other known or putative tumour-suppressor genes present
on the long arm ofchromosome 17 include Nfl, the gene for
neurofibromatosis type 1, which is located on 17q1 1.2. Muta-
tions in this gene have been identified in some colorectal
cancers (Li et al., 1992). The gene for early-onset breast
cancer (BRCA1) maps to 17q21 (Bowcock et al., 1993). The
prohibitin gene located on 17q21 has been postulated to act
as a tumour-suppressor (Sato et al., 1992).
The aim of the present study was to examine further the
frequency of allelic loss on 17q, to assess its relationship to
loss on 17p and to define the smallest region of overlap of
deletions (SRO) on 17q which is likely to contain the gene
that is the target of the deletions.
Mateias and methods
Tissue sanples
Specimens were collected from an unselected series of 72
patients having colorectal carcinomas resected at Royal Bris-
bane Hospital. Written informed consent was obtained from
each patient and the study was approved by the Ethics
Committee of the Royal Brisbane Hospital. Tumours were
staged according to Newland et al. (1987).
DNA extraction and hybridisation
Germline DNA was obtained from peripheral blood leuco-
cytes or normal colonic mucosa. The colorectal carcinomas
were macroscopically fractionated by a pathologist (JS) to
remove excess normal tissue. DNA was extracted by a
modification of the salt precipitation technique (Miller et al.,
1988). DNA was digested with appropriate enzymes, alkali
blotted onto charged nylon membranes and hybridised to
radiolabelled probes as previously described (Young et al.,
1992). The probes used were pI44-D6 (PstI) for D17S34
(Kondoleon et al., 1987a), pYNZ22 (Pstl) for D17S5 (Naka-
mura et al., 1988a), LEW301 (TaqI) for Dl7S58 (Barker et
al., 1987), AE25 (PstI, TaqI, BglIl) for Nil (Andersen et al.,
1991), nm23-Hl (BglII) for NME1 (Yague et al., 1991),
LEWIOI (MspI) for D17S40 (Nakamura et al., 1988b), pC63
(MspI) for D17S21 (Kondoleon et al., 1987b) and pTHH59
(PvuII) for D17S4 (Nakamura et al., 1988c). A Southern blot
example is given in Figure 1, Because probes at the p53 locus
are frequently uninformative, this locus was examined using
a dinucleotide repeat polymorphism as previously described
(Jones and Nakamura, 1992) but without radioisotope. Poly-
merase chain reaction (PCR) products were resolved on 20%
non-denaturing polyacrylamide gels and stained with ethi-
dium bromide (Figure 2). Loci were ordered according to
The NIH/CEPH Collaborative Mapping Group (1992).
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To determine the most efficient method for detecting LOH,
we compared visual and densitometric methods. Sixty-nine
neoplasms (from 51 heterozygous patients) were probed as
described above with the plasmid OLVIIEIO (MspI RFLP),
which recognises an intron of the DCC gene (Fearon et al.,
1990). Loss of alleles from this gene occurs frequently and
relatively early in the development of colorectal tumours
(Vogelstein et al., 1988, 1989) and hence will be common in
all stages, types and sites of colorectal cancers. All den-
sitometry was carried out using an LKB 2202 Ultrascan laser
densitometer. Each band was scanned three times
(left-middle- right) and the mean value recorded. Results
were also scored visually by three observers.
Analysis of densitometry data was performed using the
method of Solomon et al. (1987). Briefly, this method related
the densitometric ratio of the two alleles in each individual
tumour (AI) to the ratio of the two alleles in the normal
tissue of that patient (Al) via the ratio R=AI/AIM. A
frequency plot of R revealed a bimodal distribution. The first
peak contained ratios from those tumours with no visually
scored allele loss, and the second those with detectable loss.
When the data in the present study were plotted as above, a
bimodal distribution was also found, with the R-value at the
boundary of the first peak being 1.15. Those with R-values
above 1.15 were scored positively for loss of heterozygosity.
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Figwe 1 An example of a typical Southern blot analysis of
LOH. Paired samples of normal and tumour DNA from individ-
ual patients have been probed with LEWIOI for the locus
D17S40 (MspI RFLP). In the left panel, no LOH is present. In
the nrght panel, the allele markled by the arrowhead has been lost.
N, DNA from normal tissue; T, DNA from tumour.
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Fugwe 2 (a-c) Paired DNA samples from individual patients
amplified with the TP53 microsatellite marker (Jones and
Nakamura, 1992) in ethidium bromide-stained gels. N, DNA
from normal tissue; T, DNA from tumour, Arrowhead, position
of allelic loss.
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Only one discrepancy occurred between the visual scores and
the Solomon method, and this was at the cut-off interface.
Therefore, because visual scoring by consensus gives results
that are almost completely consistent with the objective
method of Solomon et al. (1987), it was decided to use visual
scoring for the analysis of chromosome 17.
Results
A total of 72 carcinomas were evaluated for allelic loss at
eight loci on chromosome 17. The results are summarised in
Figure 3.
In 17 cases (24%) there was no evidence of allelic loss at
any locus, suggesting that the whole chromosome was re-
tained without large areas of loss. In 23 cases (32%) all
informative loci showed allelic loss, suggesting that a whole
copy of chromosome 17 had been deleted with or without
reduplication. In 20 cases (28%) there was a pattern of allelic
loss consistent with a deletion of part of chromosome 17,
including the p53 locus. In 5 of these 20 cases the allelic loss
apparently extended across the centromere to be contiguous
with an area of allelic loss on proximal 17q. In two tumours
(3%), a deletion of the distal portion of the short arm, not
including p53, was seen. One of these tumours is tumour 7 in
Figure 4. In the other case, 17p LOH was the only LOH
found.
In 11 cases (15%), there was a pattern consistent with a
deletion of part of chromosome 17q which did not extend to
include the p53 locus (Figure 4). In 6 of these 11 cases
(subjects 1-6), there was an addtional discrete area of allelic
loss which did include the p53 locus. The 11 partial deletions
which did not include the p53 locus were examined in detail
for evidence of another target area of loss. When the maxi-
mum possible extent of each deletion was identified, they all
overlapped at the locus DI7S40, suggesting that the region
around this locus contains a suppressor gene at which the
loss is targeted.
Of the 72 carcinomas, seven (10%) were stage A, 36 (50%)
were stage B, 20 (28%) were stage C and nine (12%) were
stage D. At the p53 locus and the two closely associated
distal loci D17S5 and D17S34, allelic loss was significantly
more frequent in stage C and D carcinomas (Table I) (P<
0.05, Wilcoxon rank-sum test). In contrast, there was no
significant correlation between changes at other loci including
D17S40 and stage of the tumour (P>0.05, Wilcoxon rank-
sum test). Fifty carcinomas were left-sided and 22 right-sided.
LOH on chromosome 17 was more frequent in left-sided
tumours. Individual loci which more commonly showed
allelic loss in left-sided tumours were p53, D17S5, D17S34


















































Figwe 3 Allelic loss at loci on chromosome 17 in a series of 72
colorectal carcinomas. NL/NI, number of tumIours with allelic
loss/number of tumours informative at that locus.
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Fge 4 Colorectal carcinomas showing allelic loss on chromo-
some 17q which is not contiguous with allelic loss at the p53
locus on 17p. The smallest region of overlap of the deletions
(SRO) includes the locus D17S40.
Table I Allelic loss in relation to tumour stage of colorectal
carcinomas
Stage (%)
Locus A B C D
p53a 40 (2/5)b 59 (19/32) 89 (17/19) 71 (5/7)
DI7S5C 33 (1/3) 65 (11/17) 100 (9/9) 100 (4/4)
D17S34C 0 (0/5) 62 (18/29) 75 (9/12) 88 (7/8)
aWikoxon rank-sum test, P<0.05. bPerontage of tumours showing
allelic loss at the locus. Numbers in brackets are the number showing
allelic loss/number of tunours informative at that locus. cWilcoxon
rank-sum test, P<0.01.
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This study shows that allelic loss on chromosome 17q occurs
in over 50% of colorectal carcinomas. In many cases the
region of allelic loss is large and includes the tumour-
suppressor gene p53 on 17p. However, in some cases the
region deleted does not include p53, and in these cases the
SRO includes the locus D17S40 on 17q22-23, suggesting
that this region is a target area of allelic loss. In all, 64% of
cancers showed allelic loss at D17S40. It should be noted
that only one case (subject 6 in Figure 4) excludes NMEI,
BRCA1 and prohibitin from the SRO. The results from this
subject are particularly difficult to interpret because studies of
D17S40 are not informative in this individual. Further
studies in more individuals with partial deletions not includ-
ing p53 would be worthwhile to confirm these data and more
finely map the SRO.
Studies of breast and ovanran carcinomas have shown
regions of frequent LOH on 17q. There is evidence for a
target area of loss on proximal 17q probably including
BRCA1 (Futreal et al., 1992; Cornelis et al., 1993; Lindblom
et al., 1993; Saito et al., 1993). Some of these studies and
others have also provided evidence for a more distal target
region of loss on 17q in breast and ovarian cancer (Cropp et
al., 1990; Eccles et al., 1992; Cornelis et al., 1993; Jacobs et
al., 1993; Lindblom et al., 1993). The distal target region of
loss in recent large series of breast cancers (Cornelis et al.,
1993) and ovarian cancers (Godwin et al., 1994) includes the
same region as we have identified in the present study. This
supports the presence of an as yet undiscovered tumour-
suppressor gene in this region of 17q since such genes are
often inactivated in several different tumour types.
Our study is consistent with frequent inactivation ofp53 in
colorectal carcinomas. It also provides some evidence for an
additional tumour-suppressor gene telomeric to p53, as has
been proposed by Coles et al. (1990) in breast carcinomas. In
the current study, 2 of 72 carcinomas showed allelic loss of
distal 17p loci while retaining heterozygosity at p53.
Although our study did not distinguish whether apparent
allelic loss was due to loss of genetic material or to gene
amplification, it is likely that the great majority of the
changes observed were due to loss. Cytogenetically, trisomy
17 is rare in colorectal cancers (Muleris et al., 1990). Gene
amplification has not been demonstrated to be common in
colorectal cancer and would be unlikely to affect the large
segments ofthe chromosome in which allelic loss was demon-
strated in most of the cancers examined.
In summary, this study shows that the patterns of allelic
loss on chromosome 17 in colorectal carcinoma are complex.
It is consistnt with frequent inactivation ofthep53 gene and
perhaps another gene telomeric to p53 on 17p but provides
evidence that inactivation of one or more genes on 17q also
provides a growth advantage in many cases. Genes close to
D17S40 at 17q22-23 are especially likely to be important.
Investigation of mutations, polymorphisms and imprinting
status of potential target genes will be important as these
genes are identified.
Abbreviedo
PCR, polymerase chain reaction; SRO, smallest region of overlap of
deletions; LOH, loss of heterozygosity.
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